Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia.

Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH.

Acta Neuropathol Commun. 2018 May 10;6(1):39. doi: 10.1186/s40478-018-0541-1.

2.

Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146].

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2018 Aug;116:180. doi: 10.1016/j.nbd.2018.02.018. Epub 2018 Mar 20. No abstract available.

PMID:
29571591
3.

Update on Molecular Imaging in Parkinson's Disease.

Liu ZY, Liu FT, Zuo CT, Koprich JB, Wang J.

Neurosci Bull. 2018 Apr;34(2):330-340. doi: 10.1007/s12264-017-0202-6. Epub 2017 Dec 27. Review.

PMID:
29282614
4.

Reply to "Can STN DBS protect both nigral somata and innervation of the striatum?"

Koprich JB, Brotchie JM, Musacchio T, Volkmann J, Ip CW.

Ann Neurol. 2017 Nov;82(5):856. doi: 10.1002/ana.25066. Epub 2017 Oct 26. No abstract available.

PMID:
28985651
5.

Animal models of α-synucleinopathy for Parkinson disease drug development.

Koprich JB, Kalia LV, Brotchie JM.

Nat Rev Neurosci. 2017 Sep;18(9):515-529. doi: 10.1038/nrn.2017.75. Epub 2017 Jul 13. Review.

PMID:
28747776
6.

Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism.

Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Khan MH, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE.

Neurobiol Dis. 2017 Oct;106:133-146. doi: 10.1016/j.nbd.2017.06.009. Epub 2017 Jul 1. Erratum in: Neurobiol Dis. 2018 Mar 20;:.

PMID:
28673739
7.

Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T α-synuclein Parkinson's disease rat model.

Musacchio T, Rebenstorff M, Fluri F, Brotchie JM, Volkmann J, Koprich JB, Ip CW.

Ann Neurol. 2017 Jun;81(6):825-836. doi: 10.1002/ana.24947. Epub 2017 Jun 9.

8.

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.

Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.

Acta Neuropathol Commun. 2017 Feb 1;5(1):11. doi: 10.1186/s40478-017-0416-x.

10.

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era.

Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE.

Trends Neurosci. 2016 Nov;39(11):750-762. doi: 10.1016/j.tins.2016.09.003. Epub 2016 Oct 21. Review.

PMID:
27776749
11.

Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury.

Ip CW, Isaias IU, Kusche-Tekin BB, Klein D, Groh J, O'Leary A, Knorr S, Higuchi T, Koprich JB, Brotchie JM, Toyka KV, Reif A, Volkmann J.

Acta Neuropathol Commun. 2016 Oct 3;4(1):108.

12.

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.

13.

Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease.

He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J.

Mol Neurobiol. 2016 May;53(4):2258-68. doi: 10.1007/s12035-015-9173-7. Epub 2015 May 14.

PMID:
25972237
14.

L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat.

Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM.

Behav Pharmacol. 2015 Feb;26(1-2):101-8. doi: 10.1097/FBP.0000000000000096.

PMID:
25303957
15.

UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.

Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM.

Neuropharmacology. 2014 Jul;82:76-87. doi: 10.1016/j.neuropharm.2014.01.012. Epub 2014 Jan 18.

PMID:
24447715
16.

TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque.

Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM.

Neuropharmacology. 2013 Oct;73:337-47. doi: 10.1016/j.neuropharm.2013.06.005. Epub 2013 Jun 14.

PMID:
23770260
17.

The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Pharmacol Rev. 2013 Jan 10;65(1):171-222. doi: 10.1124/pr.111.005678. Print 2013 Jan. Review.

18.

The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques.

Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM.

Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:151-6. doi: 10.1016/j.pnpbp.2012.12.008. Epub 2013 Jan 7.

PMID:
23306217
19.

Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.

Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM.

Eur J Neurosci. 2013 Mar;37(5):831-8. doi: 10.1111/ejn.12093. Epub 2013 Jan 3.

PMID:
23281915
20.

L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.

Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM.

Neuropharmacology. 2012 Oct;63(5):829-36. doi: 10.1016/j.neuropharm.2012.06.012. Epub 2012 Jun 18.

PMID:
22722022

Supplemental Content

Loading ...
Support Center